Document_And_Entity_Informatio
Document And Entity Information | 9 Months Ended | |
Apr. 30, 2015 | Jun. 02, 2015 | |
Document and Entity Information [Abstract] | ||
Entity Registrant Name | ENZO BIOCHEM INC | |
Document Type | 10-Q | |
Current Fiscal Year End Date | -24 | |
Entity Common Stock, Shares Outstanding | 46,059,000 | |
Amendment Flag | FALSE | |
Entity Central Index Key | 316253 | |
Entity Current Reporting Status | Yes | |
Entity Voluntary Filers | No | |
Entity Filer Category | Accelerated Filer | |
Entity Well-known Seasoned Issuer | No | |
Document Period End Date | 30-Apr-15 | |
Document Fiscal Year Focus | 2015 | |
Document Fiscal Period Focus | Q3 |
CONSOLIDATED_BALANCE_SHEETS
CONSOLIDATED BALANCE SHEETS (USD $) | Apr. 30, 2015 | Jul. 31, 2014 |
In Thousands, unless otherwise specified | ||
ASSETS | ||
Cash and cash equivalents | $14,375 | $17,455 |
Accounts receivable, net of allowances | 11,613 | 12,470 |
Inventories | 7,978 | 8,690 |
Prepaid expenses and other | 2,099 | 2,121 |
Total current assets | 36,065 | 40,736 |
Property, plant and equipment, net | 7,955 | 7,730 |
Goodwill | 7,452 | 7,452 |
Intangible assets, net | 6,658 | 8,108 |
Other assets | 386 | 385 |
Total assets | 58,516 | 64,411 |
LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
Loan payable | 3,013 | 3,013 |
Accounts payable – trade | 7,612 | 8,245 |
Accrued liabilities | 11,060 | 12,917 |
Other current liabilities | 851 | 790 |
Total current liabilities | 22,536 | 24,965 |
Deferred taxes | 95 | 183 |
Other liabilities | 1,825 | 2,313 |
Total liabilities | 24,456 | 27,461 |
Commitments and contingencies | ||
Stockholders’ equity: | ||
Preferred Stock, $.01 par value; authorized 25,000,000 shares; no shares issued or outstanding | ||
Common Stock, $.01 par value; authorized 75,000,000 shares; shares issued and outstanding: 46,058,066 at April 30, 2015 and 44,239,183 at July 31, 2014 | 461 | 443 |
Additional paid-in capital | 324,856 | 317,160 |
Accumulated deficit | -293,124 | -282,397 |
Accumulated other comprehensive income | 1,867 | 1,744 |
Total stockholders’ equity | 34,060 | 36,950 |
Total liabilities and stockholders’ equity | $58,516 | $64,411 |
CONSOLIDATED_BALANCE_SHEETS_Pa
CONSOLIDATED BALANCE SHEETS (Parentheticals) (USD $) | Apr. 30, 2015 | Jul. 31, 2014 |
Preferred Stock, par value (in Dollars per share) | $0.01 | $0.01 |
Preferred Stock, shares authorized | 25,000,000 | 25,000,000 |
Preferred Stock, shares issued | 0 | 0 |
Preferred Stock, shares outstanding | 0 | 0 |
Common Stock, par value (in Dollars per share) | $0.01 | $0.01 |
Common Stock, shares authorized | 75,000,000 | 75,000,000 |
Common Stock, shares issued | 46,058,066 | 44,239,183 |
Common Stock, shares outstanding | 46,058,066 | 44,239,183 |
CONSOLIDATED_STATEMENTS_OF_OPE
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, except Per Share data, unless otherwise specified | Apr. 30, 2015 | Apr. 30, 2014 | Apr. 30, 2015 | Apr. 30, 2014 |
Revenues: | ||||
Clinical laboratory services | $15,657 | $14,542 | $46,204 | $43,250 |
Product revenues | 7,906 | 8,707 | 23,631 | 24,424 |
Royalty and license fee income | 423 | 729 | 2,067 | 3,366 |
Total revenues | 23,986 | 23,978 | 71,902 | 71,040 |
Operating expenses: | ||||
Cost of clinical laboratory services | 9,724 | 9,784 | 29,100 | 28,785 |
Cost of product revenues | 3,779 | 3,800 | 11,292 | 11,511 |
Research and development | 809 | 849 | 2,434 | 2,498 |
Selling, general, and administrative | 10,146 | 10,605 | 30,101 | 31,217 |
Provision for uncollectible accounts receivable | 589 | 684 | 1,731 | 2,468 |
Legal fee expense | 1,955 | 1,911 | 7,225 | 4,788 |
Legal settlements, net | -170 | -3,100 | -170 | -3,100 |
Total operating expenses | 26,832 | 24,533 | 81,713 | 78,167 |
Operating loss | -2,846 | -555 | -9,811 | -7,127 |
Other income (expense): | ||||
Interest | -58 | -47 | -176 | -161 |
Other | 26 | 10 | 28 | 85 |
Foreign exchange (loss) gain | -125 | 144 | -856 | 460 |
Loss before income taxes | -3,003 | -448 | -10,815 | -6,743 |
Benefit (provision) for income taxes | 96 | -7 | 88 | -65 |
Net loss | ($2,907) | ($455) | ($10,727) | ($6,808) |
Net loss per common share: | ||||
Basic and diluted (in Dollars per share) | ($0.06) | ($0.01) | ($0.24) | ($0.16) |
Weighted average common shares outstanding: | ||||
Basic and diluted (in Shares) | 45,797 | 43,243 | 45,120 | 42,062 |
CONSOLIDATED_STATEMENTS_OF_COM
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, unless otherwise specified | Apr. 30, 2015 | Apr. 30, 2014 | Apr. 30, 2015 | Apr. 30, 2014 |
Net loss | ($2,907) | ($455) | ($10,727) | ($6,808) |
Other comprehensive income (loss): | ||||
Foreign currency translation adjustments | -20 | -21 | 123 | -112 |
Comprehensive loss | ($2,927) | ($476) | ($10,604) | ($6,920) |
CONSOLIDATED_STATEMENT_OF_STOC
CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (USD $) | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | AOCI Attributable to Parent [Member] | Total |
In Thousands, except Share data | |||||
Balance at Jul. 31, 2014 | $443 | $317,160 | ($282,397) | $1,744 | $36,950 |
Balance (in Shares) at Jul. 31, 2014 | 44,239,183 | ||||
Net loss for the period ended April 30, 2015 | -10,727 | -10,727 | |||
Vesting of restricted stock (in Shares) | 15,419 | ||||
Share-based compensation charges | 319 | 319 | |||
Net proceeds from issuance of common stock (net of expenses of $207) | 16 | 6,671 | 6,687 | ||
Net proceeds from issuance of common stock (net of expenses of $207) (in Shares) | 1,588,480 | ||||
Amortization of options in lieu of payment of cash bonuses | 45 | 45 | |||
Issuance of common stock 401(k) plan match | 2 | 661 | 663 | ||
Issuance of common stock 401(k) plan match (in Shares) | 214,984 | ||||
Foreign currency translation adjustments | 123 | 123 | |||
Balance at Apr. 30, 2015 | $461 | $324,856 | ($293,124) | $1,867 | $34,060 |
Balance (in Shares) at Apr. 30, 2015 | 46,058,066 |
CONSOLIDATED_STATEMENT_OF_STOC1
CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Parentheticals) (USD $) | 9 Months Ended |
In Thousands, unless otherwise specified | Apr. 30, 2015 |
Issuance of common stock, expenses | $207 |
Common Stock [Member] | |
Issuance of common stock, expenses | 207 |
Additional Paid-in Capital [Member] | |
Issuance of common stock, expenses | $207 |
CONSOLIDATED_STATEMENTS_OF_CAS
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) | 9 Months Ended | |
In Thousands, unless otherwise specified | Apr. 30, 2015 | Apr. 30, 2014 |
Cash flows from operating activities: | ||
Net loss | ($10,727) | ($6,808) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization of property, plant and equipment | 1,513 | 1,628 |
Amortization of intangible assets | 1,284 | 1,387 |
Provision for uncollectible accounts receivable | 1,731 | 2,468 |
Deferred income tax benefit | -71 | -65 |
Share-based compensation charges | 319 | 497 |
Accrual for share-based 401(k) employer match expense | 511 | 472 |
Foreign exchange loss (gain) | 640 | -454 |
Changes in operating assets and liabilities: | ||
Accounts receivable | -940 | -2,482 |
Inventories | 597 | -144 |
Prepaid expenses and other | 16 | 385 |
Accounts payable – trade | -957 | -1,063 |
Accrued liabilities, other current liabilities and other liabilities | -2,086 | 1,445 |
Total adjustments | 2,557 | 4,074 |
Net cash used in operating activities | -8,170 | -2,734 |
Cash flows from investing activities: | ||
Capital expenditures | -1,168 | -570 |
Security deposits and other | -1 | 46 |
Net cash used in investing activities | -1,169 | -524 |
Cash flows from financing activities: | ||
Net proceeds from issuance of common stock | 6,687 | 9,455 |
Proceeds from borrowings under Credit Agreement | 65,389 | 56,826 |
Repayments under Credit Agreement | -65,389 | -57,077 |
Installment loan and capital lease obligation payments | -316 | -280 |
Net cash provided by financing activities | 6,371 | 8,924 |
Effect of exchange rate changes on cash and cash equivalents | -112 | 131 |
(Decrease) increase in cash and cash equivalents | -3,080 | 5,797 |
Cash and cash equivalents - beginning of period | 17,455 | 9,007 |
Cash and cash equivalents - end of period | $14,375 | $14,804 |
Basis_of_Presentation
Basis of Presentation | 9 Months Ended |
Apr. 30, 2015 | |
Disclosure Text Block [Abstract] | |
Basis of Accounting [Text Block] | Note 1 – Basis of Presentation |
The accompanying consolidated financial statements include the accounts of Enzo Biochem, Inc. and its wholly-owned subsidiaries, Enzo Life Sciences, Enzo Clinical Labs, Enzo Therapeutics and Enzo Realty LLC, collectively referred to as the “Company” or “Companies”. The consolidated balance sheet as of April 30, 2015, the consolidated statements of operations and the consolidated statements of comprehensive income (loss) for the three and nine months ended April 30, 2015 and 2014, the consolidated statements of cash flows for the nine months ended April 30, 2015 and 2014, and the consolidated statement of stockholders’ equity for the nine months ended April 30, 2015 are unaudited. In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present fairly the financial position and operating results for the interim periods have been made. Certain information and footnote disclosure, normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States, have been condensed or omitted. The consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended July 31, 2014 and notes thereto contained in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission. The consolidated balance sheet at July 31, 2014 has been derived from the audited financial statements at that date. The results of operations for the three and nine months ended April 30, 2015 are not necessarily indicative of the results that may be expected for the fiscal year ending July 31, 2015. |
Net_loss_per_share
Net loss per share | 9 Months Ended |
Apr. 30, 2015 | |
Earnings Per Share [Abstract] | |
Earnings Per Share [Text Block] | Note 2 – Net loss per share |
Basic net income (loss) per share represents net income (loss) divided by the weighted average number of common shares outstanding during the period. As a result of the net loss for each of the three and nine month periods ended April 30, 2015 and 2014, diluted weighted average shares outstanding are the same as basic weighted average shares outstanding, and do not include the potential common shares from stock options and unvested restricted stock because to do so would be antidilutive. | |
For the three and nine months ended April 30, 2015, approximately 1,358,000 and 1,113,000 weighted average stock options were excluded from the determination of diluted weighted average shares outstanding. For the three and nine months ended April 30, 2014, approximately 1,172,000 and 905,000 weighted average stock options were excluded from the determination. For the three and nine months ended April 30, 2015, approximately 26,000 shares of unvested restricted stock were excluded from the determination of diluted weighted average shares outstanding. For the three and nine months ended April 30, 2014, approximately 52,000 shares of unvested restricted stock were excluded from the determination. |
Supplemental_disclosure_for_st
Supplemental disclosure for statement of cash flows | 9 Months Ended |
Apr. 30, 2015 | |
Supplemental Cash Flow Elements [Abstract] | |
Cash Flow, Supplemental Disclosures [Text Block] | Note 3 - Supplemental disclosure for statement of cash flows |
For the nine months ended April 30, 2015 and 2014, income taxes paid by the Company were $103 and $33, respectively. | |
For the nine months ended April 30, 2015 and 2014, interest paid by the Company was $153 and $161, respectively. | |
For the nine months ended April 30, 2015 and 2014, the Company financed $388 and $246 respectively, in machinery and transportation equipment under installment loans. | |
During the nine months ended April 30, 2015, there was a total of $147 in capital lease agreements. During the nine months ended April 30, 2014, the Company did not enter into any capital lease agreements. | |
During the nine months ended April 30, 2015, the Company recorded $45 in additional paid in capital and reduced accrued liabilities by the same amount for options previously issued in lieu of cash payment of certain incentive compensation awards. | |
During the nine months ended April 30, 2015 and 2014, the Company issued shares of common stock in settlement of its accrued share-based 401(k) employer match in the amount of $663 and $636, respectively. |
Inventories
Inventories | 9 Months Ended | ||||||||
Apr. 30, 2015 | |||||||||
Inventory Disclosure [Abstract] | |||||||||
Inventory Disclosure [Text Block] | Note 4 - Inventories | ||||||||
Inventories consist of the following: | |||||||||
April 30, | July 31, | ||||||||
2015 | 2014 | ||||||||
Raw materials | $ | 1,168 | $ | 1,092 | |||||
Work in process | 2,121 | 2,460 | |||||||
Finished products | 4,689 | 5,138 | |||||||
$ | 7,978 | $ | 8,690 | ||||||
Goodwill_and_intangible_assets
Goodwill and intangible assets | 9 Months Ended | ||||||||||||||||||||||||
Apr. 30, 2015 | |||||||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | |||||||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Text Block] | Note 5 – Goodwill and intangible assets | ||||||||||||||||||||||||
At April 30, 2015 and July 31, 2014, the Company’s net carrying amount of goodwill, related to the Clinical Labs segment, is $7,452. | |||||||||||||||||||||||||
The Company’s change in the net carrying amount of intangible assets, all of which is included in the Life Sciences segment is as follows: | |||||||||||||||||||||||||
Gross | Accumulated Amortization | Net | |||||||||||||||||||||||
31-Jul-14 | $ | 28,478 | $ | (20,370 | ) | $ | 8,108 | ||||||||||||||||||
Amortization expense | — | (1,284 | ) | (1,284 | ) | ||||||||||||||||||||
Foreign currency translation | (569 | ) | 403 | (166 | ) | ||||||||||||||||||||
30-Apr-15 | $ | 27,909 | $ | (21,251 | ) | $ | 6,658 | ||||||||||||||||||
Intangible assets consist of the following: | |||||||||||||||||||||||||
30-Apr-15 | 31-Jul-14 | ||||||||||||||||||||||||
Gross | Accumulated | Net | Gross | Accumulated | Net | ||||||||||||||||||||
Amortization | Amortization | ||||||||||||||||||||||||
Patents | $ | 11,027 | $ | (10,802 | ) | $ | 225 | $ | 11,027 | $ | (10,775 | ) | $ | 252 | |||||||||||
Customer relationships | 12,278 | (7,162 | ) | 5,116 | 12,602 | (6,565 | ) | 6,037 | |||||||||||||||||
Website and acquired content | 1,023 | (1,023 | ) | — | 1,037 | (1,037 | ) | — | |||||||||||||||||
Licensed technology and other | 515 | (433 | ) | 82 | 537 | (434 | ) | 103 | |||||||||||||||||
Trademarks | 3,066 | (1,831 | ) | 1,235 | 3,275 | (1,559 | ) | 1,716 | |||||||||||||||||
Total | $ | 27,909 | $ | (21,251 | ) | $ | 6,658 | $ | 28,478 | $ | (20,370 | ) | $ | 8,108 | |||||||||||
At April 30, 2015, information with respect to intangibles assets acquired is as follows: | |||||||||||||||||||||||||
Useful life | Weighted average | ||||||||||||||||||||||||
assigned (years) | remaining useful life | ||||||||||||||||||||||||
Minimum | Maximum | ||||||||||||||||||||||||
Customer relationships | 8 | 15 | 5.5 years | ||||||||||||||||||||||
Trademarks | 5 | 2.5 years | |||||||||||||||||||||||
Other intangibles | 4 | 5 | 0.5 year | ||||||||||||||||||||||
At April 30, 2015, the weighted average useful life of amortizable intangible assets is approximately 4.5 years. |
Loan_Payable
Loan Payable | 9 Months Ended |
Apr. 30, 2015 | |
Debt Disclosure [Abstract] | |
Debt Disclosure [Text Block] | Note 6 - Loan Payable |
On June 7, 2013, the Company entered into a secured Revolving Loan and Security Agreement (the “Credit Agreement”) among the Company and certain of its subsidiaries, with Enzo Therapeutics as a guarantor, and Healthcare Finance Group, LLC (the “Lender). The Credit Agreement, which expires in December 2016, provides for borrowings against eligible US receivables, as defined, of the Clinical Lab and Life Science segments up to $8.0 million at defined eligibility percentages and provides for additional borrowings of $4.0 million for increased eligible assets. Debt issuance costs of $281 are being amortized over the life of the Credit Agreement. If the amount of borrowings outstanding under the revolving credit facility exceeds the borrowing base then in effect, or the Lender requires a reserve, the Company will be required to repay such borrowings in an amount sufficient to eliminate such excess. Interest on advances, payable monthly, is based on the three month LIBOR rate, with a floor of 1.25% plus an applicable margin of 4.0%, In the event of any default, the interest rate may be increased 3.0% over the current rate. The facility also carries a non-utilization fee of 0.50% per annum, payable monthly, on the unused portion of the Credit Agreement. The Credit Agreement requires a minimum borrowing of $2.0 million. At April 30, 2015 and July 31, 2014, the borrowings under the Credit Agreement related to the Clinical Labs and Life Sciences receivables aggregated $3.0 million with an additional availability of $2.7 million at April 30, 2015 | |
The Company’s obligations under the Credit Agreement are secured by primarily all the unencumbered U.S. assets of the Company, excluding buildings and intellectual property which the Lender has a negative pledge, and the capital stock of subsidiaries. The Credit Agreement includes customary affirmative and negative covenants and events of default and requires maximum levels of cash usage and minimum levels of liquidity, as defined, and provides for increased liquidity levels if operating results are not achieved. Negative covenants include among others, limitations on additional debt, liens, loans or investments, distributions, asset sales and affiliate transactions. Events of default include non-payment of principal and interest on debt outstanding, non-performance of covenants, material change in business, breach of representations, bankruptcy and insolvency, material judgments and changes in control. As of April 30, 2015, the Company is in compliance with the financial covenants. |
Accrued_Liabilities_and_Other_
Accrued Liabilities and Other Current Liabilities | 9 Months Ended | ||||||||
Apr. 30, 2015 | |||||||||
Payables and Accruals [Abstract] | |||||||||
Accounts Payable and Accrued Liabilities Disclosure [Text Block] | Note 7 – Accrued Liabilities and Other Current Liabilities | ||||||||
Accrued liabilities consist of the following: | |||||||||
April 30, | July 31, | ||||||||
2015 | 2014 | ||||||||
Legal fee expense | $ | 4,831 | $ | 4,721 | |||||
Payroll, benefits, and commissions | 3,443 | 4,959 | |||||||
Professional fees | 654 | 638 | |||||||
Research and development | 300 | 400 | |||||||
Other | 1,832 | 2,199 | |||||||
$ | 11,060 | $ | 12,917 | ||||||
Other current liabilities consist of the following: | |||||||||
April 30, | July 31, | ||||||||
2015 | 2014 | ||||||||
Accrued legal settlement | $ | 400 | $ | 400 | |||||
Installment loans | 302 | 241 | |||||||
Capital lease obligations | 149 | 149 | |||||||
$ | 851 | $ | 790 | ||||||
Other_liabilities
Other liabilities | 9 Months Ended | ||||||||
Apr. 30, 2015 | |||||||||
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract] | |||||||||
Other Liabilities Disclosure [Text Block] | Note 8 – Other Liabilities | ||||||||
Other liabilities consist of the following: | |||||||||
April 30, | July 31, | ||||||||
2015 | 2014 | ||||||||
Accrued legal settlement | $ | 1,200 | $ | 1,600 | |||||
Capital lease obligations, net of short term | 249 | 344 | |||||||
Installment loans, net of short term | 376 | 369 | |||||||
$ | 1,825 | $ | 2,313 | ||||||
As of April 30, 2015, future minimum payments under the capital leases, net of interest of $37 aggregates $516, including a short term debt portion of $149 included in other current liabilities. Future minimum payments under the installment loans aggregate $586, including a short term portion of $302 included in other current liabilities. A total of $1.6 million was recorded in other current liabilities and in other liabilities as accrued legal settlement which is further discussed in Note 13 - Contingencies. |
Stockholders_Equity
Stockholders' Equity | 9 Months Ended | ||||||||||||||||
Apr. 30, 2015 | |||||||||||||||||
Stockholders' Equity Note [Abstract] | |||||||||||||||||
Stockholders' Equity Note Disclosure [Text Block] | Note 9 – Stockholders’ Equity | ||||||||||||||||
Controlled Equity Offering | |||||||||||||||||
On March 28, 2013, the Company entered into a Controlled Equity OfferingSM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co., as sales agent (“Cantor”). Under the Sales Agreement, the Company may offer and sell, from time to time, through Cantor, shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), having an aggregate offering price of up to $20.0 million (the “Shares”). The Company will pay Cantor a commission of 3.0% of the aggregate gross proceeds received under the Sales Agreement. The Company is not obligated to make any sales of the Shares under the Sales Agreement. The offering of Shares pursuant to the Sales Agreement will terminate upon the earlier of (a) the sale of all of the Shares subject to the Sales Agreement or (b) the termination of the Sales Agreement by Cantor or the Company, as permitted therein. The Shares were initially issued pursuant to the Company’s Registration Statement on Form S-3 which was declared effective on August 5, 2010 and a prospectus supplement, dated March 28, 2013, and more recently under the Company’s current Registration Statement on Form S-3 which was declared effective on August 13, 2013 and a prospectus supplement dated August 1, 2013, filed by the Company with the Securities and Exchange Commission (the “SEC”). | |||||||||||||||||
During the nine months ended April 30, 2015, the Company sold an aggregate of 1,588,480 shares of Common Stock under the Sales Agreement at an average price of $4.34 per share and received proceeds of approximately $6.7 million, net of expenses of $207. For the nine months ended April 30, 2014, the Company sold an aggregate of 3,018,112 shares of Common Stock under the Sales Agreement at an average price of $3.23 per share and received proceeds of approximately $9.5 million, net of expenses of $293. | |||||||||||||||||
On December 31, 2014, the Sales Agreement was amended in order for the Company to offer and sell, through Cantor, acting as agent, additional shares of Common Stock having an aggregate offering price of $20.0 million. In connection with the amendment to the Sales Agreement, the Company also filed with the SEC a prospectus supplement dated December 31, 2014. | |||||||||||||||||
Share-based compensation | |||||||||||||||||
The Company has an incentive stock option plan (the “1999 Plan”), an incentive stock option and restricted stock award plan (the “2005 Plan”), and a long term incentive share award plan, (the “2011 Incentive Plan”), which are more fully described in Note 10 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended July 31, 2014. The 2011 Plan, which is the only plan from which awards may now be granted, provides for the award to eligible employees, officers, directors, consultants and other persons of stock options, stock appreciation rights (SARs), restricted stock, restricted stock units, performance awards, and other stock-based awards. | |||||||||||||||||
The amounts of share-based compensation expense recognized in the periods presented are as follows: | |||||||||||||||||
Three months ended | Nine months ended | ||||||||||||||||
April 30, | April 30, | ||||||||||||||||
2015 | 2014 | 2015 | 2014 | ||||||||||||||
Stock options | $ | 104 | $ | 255 | $ | 283 | $ | 367 | |||||||||
Restricted stock | 9 | 28 | 36 | 130 | |||||||||||||
$ | 113 | $ | 283 | $ | 319 | $ | 497 | ||||||||||
The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations: | |||||||||||||||||
Three months ended | Nine months ended | ||||||||||||||||
April 30, | April 30, | ||||||||||||||||
2015 | 2014 | 2015 | 2014 | ||||||||||||||
Cost of clinical laboratory services | $ | 3 | $ | 3 | $ | 9 | $ | 7 | |||||||||
Research and development | — | — | 2 | 1 | |||||||||||||
Selling, general and administrative | 110 | 280 | 308 | 489 | |||||||||||||
$ | 113 | $ | 283 | $ | 319 | $ | 497 | ||||||||||
0 excess tax benefits were recognized during the nine month periods ended April 30, 2015 and 2014. | |||||||||||||||||
Stock Option Plans | |||||||||||||||||
The following table summarizes stock option activity during the nine month period ended April 30, 2015: | |||||||||||||||||
Options | Weighted | Weighted | Aggregate | ||||||||||||||
Average | Average | Intrinsic | |||||||||||||||
Exercise | Remaining | Value (000s) | |||||||||||||||
Price | Contractual | ||||||||||||||||
Term | |||||||||||||||||
Outstanding at July 31, 2014 | 1,155,910 | $ | 5.03 | ||||||||||||||
Awarded | 383,873 | $ | 3.57 | ||||||||||||||
Exercised | — | $ | — | ||||||||||||||
Cancelled or expired | (181,900 | ) | $ | 16.82 | |||||||||||||
Outstanding at end of period | 1,357,883 | $ | 3.05 | 2.7 years | $ | 39 | |||||||||||
Exercisable at end of period | 782,688 | $ | 2.88 | 2.2 years | $ | 20 | |||||||||||
As of April 30, 2015, the total future compensation cost related to non-vested options, not yet recognized in the statements of operations, was $0.6 million and the weighted average period over which the remaining expense of these awards is expected to be recognized is eighteen months. | |||||||||||||||||
The intrinsic value of stock option awards that vested during the fiscal year represents the value of the Company’s closing stock price on the last trading day of the fiscal year in excess of the exercise price multiplied by the number of options that vested. | |||||||||||||||||
Restricted Stock Awards | |||||||||||||||||
A summary of the activity pursuant to the Company’s unvested restricted stock awards for the nine months ended April 30, 2015 is as follows: | |||||||||||||||||
Awards | Weighted | ||||||||||||||||
Average | |||||||||||||||||
Award Price | |||||||||||||||||
Outstanding at July 31, 2014 | 42,502 | $ | 5.74 | ||||||||||||||
Awarded | 4,250 | $ | 4.75 | ||||||||||||||
Vested | (15,419 | ) | $ | (2.41 | ) | ||||||||||||
Forfeited | (5,500 | ) | $ | (3.32 | ) | ||||||||||||
Unvested at end of period | 25,833 | $ | 8.07 | ||||||||||||||
The fair value of a restricted stock award is determined based on the closing stock price on the award date. As of April 30, 2015, there was approximately $0.1 million of unrecognized compensation cost related to unvested restricted stock-based compensation to be recognized over a weighted average remaining period of approximately eighteen months. The fair value of the awards that vested during the nine months ended April 30, 2015 and 2014 was $67 and $62, respectively. | |||||||||||||||||
The total number of shares available for grant as equity awards from the 2011 Incentive Plan is approximately 1,297,000 shares as of April 30, 2015. | |||||||||||||||||
During the nine months ended April 30, 2015, the Company settled its accrual of $663 to match its employees’ 401(k) contributions by issuing 214,984 shares, representing the fair value of the shares at the date of issuance, and adjusted common stock and additional paid in capital by the same amount. | |||||||||||||||||
During the nine months ended April 30, 2014, the Company settled its accrual of $636 to match its employees’ 401(k) contributions by issuing 165,646 shares, representing the fair value of the shares at the date of issuance, and adjusted common stock and additional paid in capital by the same amount. |
Income_taxes
Income taxes | 9 Months Ended |
Apr. 30, 2015 | |
Income Tax Disclosure [Abstract] | |
Income Tax Disclosure [Text Block] | Note 10 - Income taxes |
At the end of each interim reporting period, the Company estimates its effective income tax rate expected to be applicable for the full year. This estimate is used to determine the income tax provision or benefit on a year-to-date basis and may change in subsequent interim periods. | |
The Company’s effective tax rate (benefit) provision for the three months ended April 30, 2015 was (3.2%) compared to a 1.5% provision during the three months ended April 30, 2014. The Company’s effective tax rate provision was deminimus for the nine months ended April 30, 2015 and 2014. The tax provision or benefit for the periods was based on state, local and foreign taxes, net of the benefit for amortization of foreign intangibles. The Company’s effective tax rate for both periods differed from the expected net operating loss carryforward benefit at the U.S. federal statutory rate of 34% primarily due to the inability to recognize such benefit. The carryforward benefit cannot be recognized because of uncertainties relating to future taxable income in terms of both its timing and its sufficiency, which would enable the Company to realize the federal carryforward benefit. | |
The Company files a consolidated Federal income tax return. The Company files combined returns with California, Michigan and New York State and City for certain subsidiaries. Other subsidiaries file separate state and foreign tax returns. |
Royalty_and_licensing_income
Royalty and licensing income | 9 Months Ended |
Apr. 30, 2015 | |
Royalty And Licensing Income [Abstract] | |
Royalty And Licensing Income [Text Block] | Note 11 – Royalty and licensing income |
The Company’s Life Science segment has a license agreement with QIAGEN Gaithersburg Inc. (“Qiagen”) that began in 2005, whereby the Company earns quarterly royalties on the net sales of Qiagen products subject to the license until the expiration of the patent on April 24, 2018. During the three months ended April 30, 2015 and 2014, the Company recorded royalty income under the agreement of approximately $0.4 million and $0.7 million respectively. During the nine months ended April 30, 2015 and 2014, the Company recorded royalty income under the agreement of approximately $2.1 million and $3.4 million respectively. |
Segment_reporting
Segment reporting | 9 Months Ended | ||||||||||||||||||||
Apr. 30, 2015 | |||||||||||||||||||||
Segment Reporting [Abstract] | |||||||||||||||||||||
Segment Reporting Disclosure [Text Block] | Note 12 – Segment reporting | ||||||||||||||||||||
The Company has three reportable segments: Clinical Labs, Life Sciences, and Therapeutics. The Clinical Labs segment provides diagnostic services to the health care community. The Company’s Life Sciences segment develops, manufactures, and markets products to research and pharmaceutical customers. The Company’s Therapeutic segment conducts research and development activities for therapeutic drug candidates. The Company evaluates segment performance based on segment income (loss) before taxes. Costs excluded from segment income (loss) before taxes and reported as “Other” consist of corporate general and administrative costs which are not allocable to the three reportable segments. | |||||||||||||||||||||
Legal fee expense incurred to defend the Company’s intellectual property and other general corporate matters is considered a component of the Other segment. Legal fee expense specific to other segments’ activities has been allocated to those segments. | |||||||||||||||||||||
Management of the Company assesses assets on a consolidated basis only and, therefore, assets by reportable segment have not been included in the reportable segments below. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies contained in the Company’s Annual Report on Form 10-K for the year ended July 31, 2014. | |||||||||||||||||||||
The following financial information represents the operating results of the reportable segments of the Company: | |||||||||||||||||||||
Three months ended April 30, 2015 | |||||||||||||||||||||
Clinical | Life | Therapeutics | Other | Consolidated | |||||||||||||||||
Labs | Sciences | ||||||||||||||||||||
Revenues: | |||||||||||||||||||||
Clinical laboratory services | $ | 15,657 | — | — | — | $ | 15,657 | ||||||||||||||
Product revenues | — | $ | 7,906 | — | — | 7,906 | |||||||||||||||
Royalty and license fee income | — | 423 | — | — | 423 | ||||||||||||||||
15,657 | 8,329 | — | — | 23,986 | |||||||||||||||||
Operating expenses: | |||||||||||||||||||||
Cost of clinical laboratory services | 9,724 | — | — | — | 9,724 | ||||||||||||||||
Cost of product revenues | — | 3,779 | — | — | 3,779 | ||||||||||||||||
Research and development | — | 704 | $ | 105 | — | 809 | |||||||||||||||
Selling, general and administrative | 4,935 | 3,031 | — | $ | 2,180 | 10,146 | |||||||||||||||
Provision for uncollectible accounts receivable | 631 | (42 | ) | — | — | 589 | |||||||||||||||
Legal fee expense | 42 | (22 | ) | — | 1,935 | 1,955 | |||||||||||||||
Legal settlement, net | — | (170 | ) | — | — | (170 | ) | ||||||||||||||
Total operating expenses | 15,332 | 7,280 | 105 | 4,115 | 26,832 | ||||||||||||||||
Operating income (loss) | 325 | 1,049 | (105 | ) | (4,115 | ) | (2,846 | ) | |||||||||||||
Other income (expense) | |||||||||||||||||||||
Interest | (23 | ) | 6 | — | (41 | ) | (58 | ) | |||||||||||||
Other | 11 | 2 | — | 13 | 26 | ||||||||||||||||
Foreign exchange loss | — | (125 | ) | — | — | (125 | ) | ||||||||||||||
Income (loss) before income taxes | $ | 313 | $ | 932 | $ | (105 | ) | $ | (4,143 | ) | $ | (3,003 | ) | ||||||||
Depreciation and amortization included above | $ | 358 | $ | 543 | $ | — | $ | 22 | $ | 923 | |||||||||||
Share-based compensation included in above: | |||||||||||||||||||||
Cost of clinical laboratory services | $ | 3 | — | — | — | $ | 3 | ||||||||||||||
Research and development | — | $ | — | — | — | — | |||||||||||||||
Selling, general and administrative | 9 | 6 | — | $ | 95 | 110 | |||||||||||||||
Total | $ | 12 | $ | 6 | — | $ | 95 | $ | 113 | ||||||||||||
Capital expenditures | $ | 453 | $ | 58 | $ | — | $ | 4 | $ | 515 | |||||||||||
Three months ended April 30, 2014 | |||||||||||||||||||||
Clinical | Life | Therapeutics | Other | Consolidated | |||||||||||||||||
Labs | Sciences | ||||||||||||||||||||
Revenues: | |||||||||||||||||||||
Clinical laboratory services | $ | 14,542 | — | — | — | $ | 14,542 | ||||||||||||||
Product revenues | — | $ | 8,707 | — | — | 8,707 | |||||||||||||||
Royalty and license fee income | — | 729 | — | — | 729 | ||||||||||||||||
14,542 | 9,436 | — | — | 23,978 | |||||||||||||||||
Operating expenses: | |||||||||||||||||||||
Cost of clinical laboratory services | 9,784 | — | — | — | 9,784 | ||||||||||||||||
Cost of product revenues | — | 3,800 | — | — | 3,800 | ||||||||||||||||
Research and development | — | 599 | $ | 250 | — | 849 | |||||||||||||||
Selling, general and administrative | 5,091 | 3,278 | — | $ | 2,236 | 10,605 | |||||||||||||||
Provision for uncollectible accounts receivable | 684 | — | — | — | 684 | ||||||||||||||||
Legal fee expense | 282 | 766 | — | 836 | 1,911 | ||||||||||||||||
Legal settlements, net | 2,000 | (5,100 | ) | — | (3,100 | ) | |||||||||||||||
Total operating expenses | 17,841 | 3,343 | 250 | 3,099 | 24,533 | ||||||||||||||||
Operating income (loss) | (3,299 | ) | 6,093 | (250 | ) | (3,099 | ) | (555 | ) | ||||||||||||
Other income (expense) | |||||||||||||||||||||
Interest | (10 | ) | 4 | — | (41 | ) | (47 | ) | |||||||||||||
Other | 7 | (2 | ) | — | 5 | 10 | |||||||||||||||
Foreign exchange gain | — | 144 | — | — | 144 | ||||||||||||||||
Income (loss) before income taxes | $ | (3,302 | ) | $ | 6,239 | $ | (250 | ) | $ | (3,135 | ) | $ | (448 | ) | |||||||
Depreciation and amortization included above | $ | 351 | $ | 614 | $ | — | $ | 23 | $ | 988 | |||||||||||
Share-based compensation included in above: | |||||||||||||||||||||
Cost of clinical laboratory services | $ | 2 | 1 | — | — | $ | 3 | ||||||||||||||
Research and development | — | — | — | — | — | ||||||||||||||||
Selling, general and administrative | 9 | $ | (4 | ) | — | $ | 275 | 280 | |||||||||||||
Total | $ | 11 | $ | (3 | ) | — | $ | 275 | $ | 283 | |||||||||||
Capital expenditures | $ | 90 | $ | 36 | $ | — | $ | — | $ | 126 | |||||||||||
The following financial information represents the operating results of the reportable segments of the Company: | |||||||||||||||||||||
Nine months ended April 30, 2015 | |||||||||||||||||||||
Clinical | Life | Therapeutics | Other | Consolidated | |||||||||||||||||
Labs | Sciences | ||||||||||||||||||||
Revenues: | |||||||||||||||||||||
Clinical laboratory services | $ | 46,204 | — | — | — | $ | 46,204 | ||||||||||||||
Product revenues | — | $ | 23,631 | — | — | 23,631 | |||||||||||||||
Royalty and license fee income | — | 2,067 | — | — | 2,067 | ||||||||||||||||
46,204 | 25,698 | — | — | 71,902 | |||||||||||||||||
Operating expenses: | |||||||||||||||||||||
Cost of clinical laboratory services | 29,100 | — | — | — | 29,100 | ||||||||||||||||
Cost of product revenues | — | 11,292 | — | — | 11,292 | ||||||||||||||||
Research and development | — | 1,887 | $ | 547 | — | 2,434 | |||||||||||||||
Selling, general and administrative | 15,090 | 8,886 | — | $ | 6,125 | 30,101 | |||||||||||||||
Provision for uncollectible accounts receivable | 1,820 | (89 | ) | — | — | 1,731 | |||||||||||||||
Legal fee expense | 174 | (74 | ) | — | 7,125 | 7,225 | |||||||||||||||
Legal settlement, net | — | (170 | ) | (170 | ) | ||||||||||||||||
Total operating expenses | 46,184 | 21,732 | 547 | 13,250 | 81,713 | ||||||||||||||||
Operating income (loss) | 20 | 3,966 | (547 | ) | (13,250 | ) | (9,811 | ) | |||||||||||||
Other income (expense) | |||||||||||||||||||||
Interest | (63 | ) | 13 | — | (126 | ) | (176 | ) | |||||||||||||
Other | 18 | (34 | ) | — | 44 | 28 | |||||||||||||||
Foreign exchange gain | — | (856 | ) | — | — | (856 | ) | ||||||||||||||
Income (loss) before income taxes | $ | (25 | ) | $ | 3,089 | $ | (547 | ) | $ | (13,332 | ) | $ | (10,815 | ) | |||||||
Depreciation and amortization included above | $ | 1,072 | $ | 1,656 | $ | 2 | $ | 67 | $ | 2,797 | |||||||||||
Share-based compensation included in above: | |||||||||||||||||||||
Cost of clinical laboratory services | $ | 9 | — | — | — | $ | 9 | ||||||||||||||
Research and development | — | $ | 2 | — | — | 2 | |||||||||||||||
Selling, general and administrative | 30 | 9 | — | $ | 269 | 308 | |||||||||||||||
Total | $ | 39 | $ | 11 | — | $ | 269 | $ | 319 | ||||||||||||
Capital expenditures | $ | 1,042 | $ | 122 | $ | — | $ | 4 | $ | 1,168 | |||||||||||
Nine months ended April 30, 2014 | |||||||||||||||||||||
Clinical | Life | Therapeutics | Other | Consolidated | |||||||||||||||||
Labs | Sciences | ||||||||||||||||||||
Revenues: | |||||||||||||||||||||
Clinical laboratory services | $ | 43,250 | — | — | — | $ | 43,250 | ||||||||||||||
Product revenues | — | $ | 24,424 | — | — | 24,424 | |||||||||||||||
Royalty and license fee income | — | 3,366 | — | — | 3,366 | ||||||||||||||||
43,250 | 27,790 | — | — | 71,040 | |||||||||||||||||
Operating expenses: | |||||||||||||||||||||
Cost of clinical laboratory services | 28,785 | — | — | — | 28,785 | ||||||||||||||||
Cost of product revenues | — | 11,511 | — | — | 11,511 | ||||||||||||||||
Research and development | 14 | 1,668 | $ | 816 | — | 2,498 | |||||||||||||||
Selling, general and administrative | 15,122 | 10,098 | — | $ | 5,997 | 31,217 | |||||||||||||||
Provision for uncollectible accounts receivable | 2,448 | 20 | — | — | 2,468 | ||||||||||||||||
Legal fee expense | 572 | 803 | — | 3,413 | 4,788 | ||||||||||||||||
Legal settlements, net | 2,000 | (5,100 | ) | (3,100 | ) | ||||||||||||||||
Total operating expenses | 48,941 | 19,000 | 816 | 9,410 | 78,167 | ||||||||||||||||
Operating income (loss) | (5,691 | ) | 8,790 | (816 | ) | (9,410 | ) | (7,127 | ) | ||||||||||||
Other income (expense) | |||||||||||||||||||||
Interest | (32 | ) | 13 | — | (142 | ) | (161 | ) | |||||||||||||
Other | 34 | 18 | — | 33 | 85 | ||||||||||||||||
Foreign exchange gain | — | 460 | — | — | 460 | ||||||||||||||||
Income (loss) before income taxes | $ | (5,689 | ) | $ | 9,281 | $ | (816 | ) | $ | (9,519 | ) | $ | (6,743 | ) | |||||||
Depreciation and amortization included above | $ | 1,061 | $ | 1,876 | $ | 6 | $ | 72 | $ | 3,015 | |||||||||||
Share-based compensation included in above: | |||||||||||||||||||||
Cost of clinical laboratory services | $ | 6 | 1 | — | — | $ | 7 | ||||||||||||||
Research and development | — | $ | 1 | — | — | 1 | |||||||||||||||
Selling, general and administrative | 28 | 5 | — | $ | 456 | 489 | |||||||||||||||
Total | $ | 34 | $ | 7 | — | $ | 456 | $ | 497 | ||||||||||||
Capital expenditures | $ | 453 | $ | 117 | $ | — | $ | — | $ | 570 | |||||||||||
Contingencies
Contingencies | 9 Months Ended |
Apr. 30, 2015 | |
Loss Contingency [Abstract] | |
Contingencies Disclosure [Text Block] | Note 13 – Contingencies |
On June 7, 2004, the Company and Enzo Life Sciences, Inc., filed suit in the United States District Court for the District of Connecticut against Applera Corporation and its wholly-owned subsidiary Tropix, Inc., which became Life Technologies, Inc. (NASDAQ:LIFE) and was acquired by Thermo Fisher Scientific, Inc. (NYSE:TMO) on February 3, 2014. The complaint alleged infringement of six patents relating to DNA sequencing systems, labeled nucleotide products, and other technology. Yale University is the owner of four of the patents and the Company is the exclusive licensee. These four patents are commonly referred to as the “Ward” patents. On November 12, 2012, a jury in New Haven found that one of these patents (United States Patent No. 5,449,667) was infringed and not proven invalid. The jury awarded $48.5 million for this infringement. On January 6, 2014, the judge awarded prejudgment interest of approximately $12.5 million and additional post-interest on the full amount will also be awarded starting November 7, 2012 until the total award is satisfied. The final award to Enzo could be reduced or be subject to possible claims from third parties. On March 16, 2015, the Court of Appeals for the Federal Circuit vacated that judgment in a decision remanding the matter to the district court for further proceedings. Enzo has moved for reconsideration of that decision by the panel and for en banc rehearing by the full Court. On June 5, 2015, the Federal Circuit remanded the case back to the District Court for further proceedings. There can be no assurance that the Company will be successful in this litigation. Even if the Company is not successful, management does not believe that there will be a significant adverse monetary impact on the Company. | |
As of August 1, 2014 the Company was engaged in litigation in the United States District Court for the Southern District of New York against Roche Diagnostic GmbH and its related company Roche Molecular Systems, Inc. (“Roche”), as declaratory judgment defendant. This case was commenced in May 2004. Roche seeks a declaratory judgment of non-breach of contract and patent invalidity against the Company. Roche has also asserted tort claims against the Company. The Company has asserted breach of contract and patent infringement causes of action against Roche. There has been extensive discovery in the case. In 2011, Roche moved for summary judgment of non-infringement regarding the Company’s patent claims. In 2012, the motion was granted in part and denied in part. In December 2012, Roche moved for summary judgment on the Company’s non-patent claims. Additional discovery was taken and the Company responded to the motions in May 2013. On December 6, 2013, the Court granted in part and denied in part Roche’s summary judgment motion. On October 22, 2014, the Court ordered that damages discovery concerning the Company’s remaining contract and patent claims and Roche’s claims should be completed by January 30, 2015, and expert discovery should be completed following the Court’s not-yet-issued claim construction ruling concerning the Company’s patent infringement claim against Roche. Roche dropped its tort claims during damages discovery. On April 28, 2015, the Court heard oral argument on claim construction issues. On May 8, 2015, Roche and the Company jointly moved the Court to extend the schedule for damages discovery until May 29, 2015, and the Court granted that motion. The litigation in the United States District Court for the Southern District of New York between the Company and Molecular Probes, Inc. terminated on May 11, 2015, with a settlement in favor of the Company in the amount of $170. The Company’s former counsel, Greenberg Traurig LLP, is also engaged in litigation against the Company in the United States District Court for the Southern District of New York concerning Greenberg Traurig’s request for a charging lien relating to its representation of the Company in the Roche and other cases. | |
On June 20, 2014, the Company, as plaintiff finalized and executed a settlement agreement with PerkinElmer, Inc., and PerkinElmer Health Sciences, Inc. (formerly known as PerkinElmer Life Sciences, Inc.) (together, “PerkinElmer”), with respect to an action between the Company and PerkinElmer before the U.S. District Court, Southern District of New York, Case No 03-CV-3817. PerkinElmer paid $7.0 million in escrow pursuant to the agreement because of a former counsel’s motion requesting a charging lien for fees allegedly owed for past services rendered to the Company. Because the settlement proceeds are held in escrow, the Company did not include the settlement or any additional amounts which may be payable to the attorney in the financial statements as of and for the fiscal year ended July 31, 2014 or for the nine months ended April 30, 2015. | |
As previously disclosed, in 2012, the Company received a Subpoena Duces Tecum (the “Subpoena”) from the Department of Health and Human Services, Office of Inspector General (“OIG”). The Subpoena was issued as part of an investigation being conducted by the US Attorney’s Office for the Eastern District of New York in conjunction with the OIG. While a number of potential issues were raised initially by the government, the investigation came to focus primarily on an alleged failure to collect diagnosis codes from physicians who ordered tests through Enzo Clinical Labs. The time period initially covered by the investigation was from 2004 through 2011. In response to the Subpoena, the Company cooperated with the government. On September 22, 2014, the Company and the U.S. Department of Justice reached a settlement agreement to resolve this matter, in substantive form as disclosed in the Company’s fiscal quarter ended April 30, 2014. During the quarter ended April, 30, 2014, the Company recorded a charge of $2.0 million in the statement of operations under legal settlements, net within the Clinical Labs segment. The settlement amount will be paid with interest over a five-year period. As of April 30, 2015, the Company carried a balance of $0.4 million as other current liabilities and $1.2 million as a non-current liability. Under certain circumstances, the Company may be required to accelerate payments and/or pay up to an additional $1.5 million based upon (i) a favorable recovery and collection related to the judgment in the Life Technologies matter discussed above, (ii) receipt of additional capital greater than $10.0 million in a fiscal year (in that case, the Company is required to pay 20% of any amount over $10.0 million plus interest, or (iii) sale of the Company. The final settlement covers the time period 2004-2014. | |
The Company is party to other claims, legal actions, complaints, and contractual disputes that arise in the ordinary course of business. The Company believes that any liability that may ultimately result from the resolution of these matters will not, individually or in the aggregate, have a material adverse effect on its financial position or results of operations |
Inventories_Tables
Inventories (Tables) | 9 Months Ended | ||||||||
Apr. 30, 2015 | |||||||||
Inventory Disclosure [Abstract] | |||||||||
Schedule of Inventory, Current [Table Text Block] | Inventories consist of the following: | ||||||||
April 30, | July 31, | ||||||||
2015 | 2014 | ||||||||
Raw materials | $ | 1,168 | $ | 1,092 | |||||
Work in process | 2,121 | 2,460 | |||||||
Finished products | 4,689 | 5,138 | |||||||
$ | 7,978 | $ | 8,690 |
Goodwill_and_intangible_assets1
Goodwill and intangible assets (Tables) | 9 Months Ended | ||||||||||||||||||||||||
Apr. 30, 2015 | |||||||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | |||||||||||||||||||||||||
Schedule of Indefinite-Lived Intangible Assets [Table Text Block] | The Company’s change in the net carrying amount of intangible assets, all of which is included in the Life Sciences segment is as follows: | ||||||||||||||||||||||||
Gross | Accumulated Amortization | Net | |||||||||||||||||||||||
31-Jul-14 | $ | 28,478 | $ | (20,370 | ) | $ | 8,108 | ||||||||||||||||||
Amortization expense | — | (1,284 | ) | (1,284 | ) | ||||||||||||||||||||
Foreign currency translation | (569 | ) | 403 | (166 | ) | ||||||||||||||||||||
30-Apr-15 | $ | 27,909 | $ | (21,251 | ) | $ | 6,658 | ||||||||||||||||||
Schedule of Intangible Assets [Table Text Block] | Intangible assets consist of the following: | ||||||||||||||||||||||||
30-Apr-15 | 31-Jul-14 | ||||||||||||||||||||||||
Gross | Accumulated | Net | Gross | Accumulated | Net | ||||||||||||||||||||
Amortization | Amortization | ||||||||||||||||||||||||
Patents | $ | 11,027 | $ | (10,802 | ) | $ | 225 | $ | 11,027 | $ | (10,775 | ) | $ | 252 | |||||||||||
Customer relationships | 12,278 | (7,162 | ) | 5,116 | 12,602 | (6,565 | ) | 6,037 | |||||||||||||||||
Website and acquired content | 1,023 | (1,023 | ) | — | 1,037 | (1,037 | ) | — | |||||||||||||||||
Licensed technology and other | 515 | (433 | ) | 82 | 537 | (434 | ) | 103 | |||||||||||||||||
Trademarks | 3,066 | (1,831 | ) | 1,235 | 3,275 | (1,559 | ) | 1,716 | |||||||||||||||||
Total | $ | 27,909 | $ | (21,251 | ) | $ | 6,658 | $ | 28,478 | $ | (20,370 | ) | $ | 8,108 | |||||||||||
Schedule of Useful Lives For Acquisitions [Table Text Block] | At April 30, 2015, information with respect to intangibles assets acquired is as follows: | ||||||||||||||||||||||||
Useful life | Weighted average | ||||||||||||||||||||||||
assigned (years) | remaining useful life | ||||||||||||||||||||||||
Minimum | Maximum | ||||||||||||||||||||||||
Customer relationships | 8 | 15 | 5.5 years | ||||||||||||||||||||||
Trademarks | 5 | 2.5 years | |||||||||||||||||||||||
Other intangibles | 4 | 5 | 0.5 year |
Accrued_Liabilities_and_Other_1
Accrued Liabilities and Other Current Liabilities (Tables) | 9 Months Ended | ||||||||
Apr. 30, 2015 | |||||||||
Payables and Accruals [Abstract] | |||||||||
Schedule of Accrued Liabilities [Table Text Block] | Accrued liabilities consist of the following: | ||||||||
April 30, | July 31, | ||||||||
2015 | 2014 | ||||||||
Legal fee expense | $ | 4,831 | $ | 4,721 | |||||
Payroll, benefits, and commissions | 3,443 | 4,959 | |||||||
Professional fees | 654 | 638 | |||||||
Research and development | 300 | 400 | |||||||
Other | 1,832 | 2,199 | |||||||
$ | 11,060 | $ | 12,917 | ||||||
Schedule of Other Current Liabilities [Table Text Block] | Other current liabilities consist of the following: | ||||||||
April 30, | July 31, | ||||||||
2015 | 2014 | ||||||||
Accrued legal settlement | $ | 400 | $ | 400 | |||||
Installment loans | 302 | 241 | |||||||
Capital lease obligations | 149 | 149 | |||||||
$ | 851 | $ | 790 |
Other_liabilities_Tables
Other liabilities (Tables) | 9 Months Ended | ||||||||
Apr. 30, 2015 | |||||||||
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract] | |||||||||
Schedule of Other Liabilities [Table Text Block] | Other liabilities consist of the following: | ||||||||
April 30, | July 31, | ||||||||
2015 | 2014 | ||||||||
Accrued legal settlement | $ | 1,200 | $ | 1,600 | |||||
Capital lease obligations, net of short term | 249 | 344 | |||||||
Installment loans, net of short term | 376 | 369 | |||||||
$ | 1,825 | $ | 2,313 |
Stockholders_Equity_Tables
Stockholders' Equity (Tables) | 9 Months Ended | ||||||||||||||||
Apr. 30, 2015 | |||||||||||||||||
Stockholders' Equity Note [Abstract] | |||||||||||||||||
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block] | The amounts of share-based compensation expense recognized in the periods presented are as follows: | ||||||||||||||||
Three months ended | Nine months ended | ||||||||||||||||
April 30, | April 30, | ||||||||||||||||
2015 | 2014 | 2015 | 2014 | ||||||||||||||
Stock options | $ | 104 | $ | 255 | $ | 283 | $ | 367 | |||||||||
Restricted stock | 9 | 28 | 36 | 130 | |||||||||||||
$ | 113 | $ | 283 | $ | 319 | $ | 497 | ||||||||||
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] | The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations: | ||||||||||||||||
Three months ended | Nine months ended | ||||||||||||||||
April 30, | April 30, | ||||||||||||||||
2015 | 2014 | 2015 | 2014 | ||||||||||||||
Cost of clinical laboratory services | $ | 3 | $ | 3 | $ | 9 | $ | 7 | |||||||||
Research and development | — | — | 2 | 1 | |||||||||||||
Selling, general and administrative | 110 | 280 | 308 | 489 | |||||||||||||
$ | 113 | $ | 283 | $ | 319 | $ | 497 | ||||||||||
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] | The following table summarizes stock option activity during the nine month period ended April 30, 2015: | ||||||||||||||||
Options | Weighted | Weighted | Aggregate | ||||||||||||||
Average | Average | Intrinsic | |||||||||||||||
Exercise | Remaining | Value (000s) | |||||||||||||||
Price | Contractual | ||||||||||||||||
Term | |||||||||||||||||
Outstanding at July 31, 2014 | 1,155,910 | $ | 5.03 | ||||||||||||||
Awarded | 383,873 | $ | 3.57 | ||||||||||||||
Exercised | — | $ | — | ||||||||||||||
Cancelled or expired | (181,900 | ) | $ | 16.82 | |||||||||||||
Outstanding at end of period | 1,357,883 | $ | 3.05 | 2.7 years | $ | 39 | |||||||||||
Exercisable at end of period | 782,688 | $ | 2.88 | 2.2 years | $ | 20 | |||||||||||
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] | A summary of the activity pursuant to the Company’s unvested restricted stock awards for the nine months ended April 30, 2015 is as follows: | ||||||||||||||||
Awards | Weighted | ||||||||||||||||
Average | |||||||||||||||||
Award Price | |||||||||||||||||
Outstanding at July 31, 2014 | 42,502 | $ | 5.74 | ||||||||||||||
Awarded | 4,250 | $ | 4.75 | ||||||||||||||
Vested | (15,419 | ) | $ | (2.41 | ) | ||||||||||||
Forfeited | (5,500 | ) | $ | (3.32 | ) | ||||||||||||
Unvested at end of period | 25,833 | $ | 8.07 |
Segment_reporting_Tables
Segment reporting (Tables) | 9 Months Ended | ||||||||||||||||||||
Apr. 30, 2015 | |||||||||||||||||||||
Segment Reporting [Abstract] | |||||||||||||||||||||
Schedule of Segment Reporting Information, by Segment [Table Text Block] | The following financial information represents the operating results of the reportable segments of the Company: | ||||||||||||||||||||
Three months ended April 30, 2015 | |||||||||||||||||||||
Clinical | Life | Therapeutics | Other | Consolidated | |||||||||||||||||
Labs | Sciences | ||||||||||||||||||||
Revenues: | |||||||||||||||||||||
Clinical laboratory services | $ | 15,657 | — | — | — | $ | 15,657 | ||||||||||||||
Product revenues | — | $ | 7,906 | — | — | 7,906 | |||||||||||||||
Royalty and license fee income | — | 423 | — | — | 423 | ||||||||||||||||
15,657 | 8,329 | — | — | 23,986 | |||||||||||||||||
Operating expenses: | |||||||||||||||||||||
Cost of clinical laboratory services | 9,724 | — | — | — | 9,724 | ||||||||||||||||
Cost of product revenues | — | 3,779 | — | — | 3,779 | ||||||||||||||||
Research and development | — | 704 | $ | 105 | — | 809 | |||||||||||||||
Selling, general and administrative | 4,935 | 3,031 | — | $ | 2,180 | 10,146 | |||||||||||||||
Provision for uncollectible accounts receivable | 631 | (42 | ) | — | — | 589 | |||||||||||||||
Legal fee expense | 42 | (22 | ) | — | 1,935 | 1,955 | |||||||||||||||
Legal settlement, net | — | (170 | ) | — | — | (170 | ) | ||||||||||||||
Total operating expenses | 15,332 | 7,280 | 105 | 4,115 | 26,832 | ||||||||||||||||
Operating income (loss) | 325 | 1,049 | (105 | ) | (4,115 | ) | (2,846 | ) | |||||||||||||
Other income (expense) | |||||||||||||||||||||
Interest | (23 | ) | 6 | — | (41 | ) | (58 | ) | |||||||||||||
Other | 11 | 2 | — | 13 | 26 | ||||||||||||||||
Foreign exchange loss | — | (125 | ) | — | — | (125 | ) | ||||||||||||||
Income (loss) before income taxes | $ | 313 | $ | 932 | $ | (105 | ) | $ | (4,143 | ) | $ | (3,003 | ) | ||||||||
Depreciation and amortization included above | $ | 358 | $ | 543 | $ | — | $ | 22 | $ | 923 | |||||||||||
Share-based compensation included in above: | |||||||||||||||||||||
Cost of clinical laboratory services | $ | 3 | — | — | — | $ | 3 | ||||||||||||||
Research and development | — | $ | — | — | — | — | |||||||||||||||
Selling, general and administrative | 9 | 6 | — | $ | 95 | 110 | |||||||||||||||
Total | $ | 12 | $ | 6 | — | $ | 95 | $ | 113 | ||||||||||||
Capital expenditures | $ | 453 | $ | 58 | $ | — | $ | 4 | $ | 515 | |||||||||||
Three months ended April 30, 2014 | |||||||||||||||||||||
Clinical | Life | Therapeutics | Other | Consolidated | |||||||||||||||||
Labs | Sciences | ||||||||||||||||||||
Revenues: | |||||||||||||||||||||
Clinical laboratory services | $ | 14,542 | — | — | — | $ | 14,542 | ||||||||||||||
Product revenues | — | $ | 8,707 | — | — | 8,707 | |||||||||||||||
Royalty and license fee income | — | 729 | — | — | 729 | ||||||||||||||||
14,542 | 9,436 | — | — | 23,978 | |||||||||||||||||
Operating expenses: | |||||||||||||||||||||
Cost of clinical laboratory services | 9,784 | — | — | — | 9,784 | ||||||||||||||||
Cost of product revenues | — | 3,800 | — | — | 3,800 | ||||||||||||||||
Research and development | — | 599 | $ | 250 | — | 849 | |||||||||||||||
Selling, general and administrative | 5,091 | 3,278 | — | $ | 2,236 | 10,605 | |||||||||||||||
Provision for uncollectible accounts receivable | 684 | — | — | — | 684 | ||||||||||||||||
Legal fee expense | 282 | 766 | — | 836 | 1,911 | ||||||||||||||||
Legal settlements, net | 2,000 | (5,100 | ) | — | (3,100 | ) | |||||||||||||||
Total operating expenses | 17,841 | 3,343 | 250 | 3,099 | 24,533 | ||||||||||||||||
Operating income (loss) | (3,299 | ) | 6,093 | (250 | ) | (3,099 | ) | (555 | ) | ||||||||||||
Other income (expense) | |||||||||||||||||||||
Interest | (10 | ) | 4 | — | (41 | ) | (47 | ) | |||||||||||||
Other | 7 | (2 | ) | — | 5 | 10 | |||||||||||||||
Foreign exchange gain | — | 144 | — | — | 144 | ||||||||||||||||
Income (loss) before income taxes | $ | (3,302 | ) | $ | 6,239 | $ | (250 | ) | $ | (3,135 | ) | $ | (448 | ) | |||||||
Depreciation and amortization included above | $ | 351 | $ | 614 | $ | — | $ | 23 | $ | 988 | |||||||||||
Share-based compensation included in above: | |||||||||||||||||||||
Cost of clinical laboratory services | $ | 2 | 1 | — | — | $ | 3 | ||||||||||||||
Research and development | — | — | — | — | — | ||||||||||||||||
Selling, general and administrative | 9 | $ | (4 | ) | — | $ | 275 | 280 | |||||||||||||
Total | $ | 11 | $ | (3 | ) | — | $ | 275 | $ | 283 | |||||||||||
Capital expenditures | $ | 90 | $ | 36 | $ | — | $ | — | $ | 126 | |||||||||||
Nine months ended April 30, 2015 | |||||||||||||||||||||
Clinical | Life | Therapeutics | Other | Consolidated | |||||||||||||||||
Labs | Sciences | ||||||||||||||||||||
Revenues: | |||||||||||||||||||||
Clinical laboratory services | $ | 46,204 | — | — | — | $ | 46,204 | ||||||||||||||
Product revenues | — | $ | 23,631 | — | — | 23,631 | |||||||||||||||
Royalty and license fee income | — | 2,067 | — | — | 2,067 | ||||||||||||||||
46,204 | 25,698 | — | — | 71,902 | |||||||||||||||||
Operating expenses: | |||||||||||||||||||||
Cost of clinical laboratory services | 29,100 | — | — | — | 29,100 | ||||||||||||||||
Cost of product revenues | — | 11,292 | — | — | 11,292 | ||||||||||||||||
Research and development | — | 1,887 | $ | 547 | — | 2,434 | |||||||||||||||
Selling, general and administrative | 15,090 | 8,886 | — | $ | 6,125 | 30,101 | |||||||||||||||
Provision for uncollectible accounts receivable | 1,820 | (89 | ) | — | — | 1,731 | |||||||||||||||
Legal fee expense | 174 | (74 | ) | — | 7,125 | 7,225 | |||||||||||||||
Legal settlement, net | — | (170 | ) | (170 | ) | ||||||||||||||||
Total operating expenses | 46,184 | 21,732 | 547 | 13,250 | 81,713 | ||||||||||||||||
Operating income (loss) | 20 | 3,966 | (547 | ) | (13,250 | ) | (9,811 | ) | |||||||||||||
Other income (expense) | |||||||||||||||||||||
Interest | (63 | ) | 13 | — | (126 | ) | (176 | ) | |||||||||||||
Other | 18 | (34 | ) | — | 44 | 28 | |||||||||||||||
Foreign exchange gain | — | (856 | ) | — | — | (856 | ) | ||||||||||||||
Income (loss) before income taxes | $ | (25 | ) | $ | 3,089 | $ | (547 | ) | $ | (13,332 | ) | $ | (10,815 | ) | |||||||
Depreciation and amortization included above | $ | 1,072 | $ | 1,656 | $ | 2 | $ | 67 | $ | 2,797 | |||||||||||
Share-based compensation included in above: | |||||||||||||||||||||
Cost of clinical laboratory services | $ | 9 | — | — | — | $ | 9 | ||||||||||||||
Research and development | — | $ | 2 | — | — | 2 | |||||||||||||||
Selling, general and administrative | 30 | 9 | — | $ | 269 | 308 | |||||||||||||||
Total | $ | 39 | $ | 11 | — | $ | 269 | $ | 319 | ||||||||||||
Capital expenditures | $ | 1,042 | $ | 122 | $ | — | $ | 4 | $ | 1,168 | |||||||||||
Nine months ended April 30, 2014 | |||||||||||||||||||||
Clinical | Life | Therapeutics | Other | Consolidated | |||||||||||||||||
Labs | Sciences | ||||||||||||||||||||
Revenues: | |||||||||||||||||||||
Clinical laboratory services | $ | 43,250 | — | — | — | $ | 43,250 | ||||||||||||||
Product revenues | — | $ | 24,424 | — | — | 24,424 | |||||||||||||||
Royalty and license fee income | — | 3,366 | — | — | 3,366 | ||||||||||||||||
43,250 | 27,790 | — | — | 71,040 | |||||||||||||||||
Operating expenses: | |||||||||||||||||||||
Cost of clinical laboratory services | 28,785 | — | — | — | 28,785 | ||||||||||||||||
Cost of product revenues | — | 11,511 | — | — | 11,511 | ||||||||||||||||
Research and development | 14 | 1,668 | $ | 816 | — | 2,498 | |||||||||||||||
Selling, general and administrative | 15,122 | 10,098 | — | $ | 5,997 | 31,217 | |||||||||||||||
Provision for uncollectible accounts receivable | 2,448 | 20 | — | — | 2,468 | ||||||||||||||||
Legal fee expense | 572 | 803 | — | 3,413 | 4,788 | ||||||||||||||||
Legal settlements, net | 2,000 | (5,100 | ) | (3,100 | ) | ||||||||||||||||
Total operating expenses | 48,941 | 19,000 | 816 | 9,410 | 78,167 | ||||||||||||||||
Operating income (loss) | (5,691 | ) | 8,790 | (816 | ) | (9,410 | ) | (7,127 | ) | ||||||||||||
Other income (expense) | |||||||||||||||||||||
Interest | (32 | ) | 13 | — | (142 | ) | (161 | ) | |||||||||||||
Other | 34 | 18 | — | 33 | 85 | ||||||||||||||||
Foreign exchange gain | — | 460 | — | — | 460 | ||||||||||||||||
Income (loss) before income taxes | $ | (5,689 | ) | $ | 9,281 | $ | (816 | ) | $ | (9,519 | ) | $ | (6,743 | ) | |||||||
Depreciation and amortization included above | $ | 1,061 | $ | 1,876 | $ | 6 | $ | 72 | $ | 3,015 | |||||||||||
Share-based compensation included in above: | |||||||||||||||||||||
Cost of clinical laboratory services | $ | 6 | 1 | — | — | $ | 7 | ||||||||||||||
Research and development | — | $ | 1 | — | — | 1 | |||||||||||||||
Selling, general and administrative | 28 | 5 | — | $ | 456 | 489 | |||||||||||||||
Total | $ | 34 | $ | 7 | — | $ | 456 | $ | 497 | ||||||||||||
Capital expenditures | $ | 453 | $ | 117 | $ | — | $ | — | $ | 570 |
Net_loss_per_share_Details
Net loss per share (Details) | 3 Months Ended | 9 Months Ended | ||
Apr. 30, 2015 | Apr. 30, 2014 | Apr. 30, 2015 | Apr. 30, 2014 | |
Weighted Average Stock Options [Member] | ||||
Net loss per share (Details) [Line Items] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 1,358,000 | 1,172,000 | 1,113,000 | 905,000 |
Unvested Restricted Stock [Member] | ||||
Net loss per share (Details) [Line Items] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 26,000 | 52,000 | 26,000 | 52,000 |
Supplemental_disclosure_for_st1
Supplemental disclosure for statement of cash flows (Details) (USD $) | 9 Months Ended | |
In Thousands, unless otherwise specified | Apr. 30, 2015 | Apr. 30, 2014 |
Supplemental Cash Flow Elements [Abstract] | ||
Income Taxes Paid | $103 | $33 |
Interest Paid | 153 | 161 |
Installment Loans Financed Amount | 388 | 246 |
Capital Lease Obligation Cost Basis | 147 | |
Adjustment to Additional Paid in Capital Stock Option Issued in Lieu of Cash Payment | 45 | |
Stock Issued During Period, Value, Employee Benefit Plan | $663 | $636 |
Inventories_Details_Schedule_o
Inventories (Details) - Schedule of inventory, current (USD $) | Apr. 30, 2015 | Jul. 31, 2014 |
In Thousands, unless otherwise specified | ||
Schedule of inventory, current [Abstract] | ||
Raw materials | $1,168 | $1,092 |
Work in process | 2,121 | 2,460 |
Finished products | 4,689 | 5,138 |
$7,978 | $8,690 |
Goodwill_and_intangible_assets2
Goodwill and intangible assets (Details) (USD $) | 9 Months Ended | |
In Thousands, unless otherwise specified | Apr. 30, 2015 | Jul. 31, 2014 |
Goodwill and intangible assets (Details) [Line Items] | ||
Goodwill | 7,452 | $7,452 |
Intangible Assets, Amortization Period [Member] | ||
Goodwill and intangible assets (Details) [Line Items] | ||
Finite-Lived Intangible Asset, Useful Life | 4 years 6 months |
Goodwill_and_intangible_assets3
Goodwill and intangible assets (Details) - Schedule of indefinite-lived intangible assets (USD $) | 9 Months Ended | ||
In Thousands, unless otherwise specified | Apr. 30, 2015 | Apr. 30, 2014 | Jul. 31, 2014 |
Indefinite-lived Intangible Assets [Line Items] | |||
Gross | $27,909 | $28,478 | |
Accumulated Amortization | -21,251 | -20,370 | |
Net | 6,658 | 8,108 | |
Amortization expense | -1,284 | -1,387 | |
Amortization expense | -1,284 | -1,387 | |
Life Sciences [Member] | |||
Indefinite-lived Intangible Assets [Line Items] | |||
Gross | 27,909 | 28,478 | |
Accumulated Amortization | -21,251 | -20,370 | |
Net | 6,658 | 8,108 | |
Amortization expense | -1,284 | ||
Amortization expense | -1,284 | ||
Foreign currency translation | -569 | ||
Foreign currency translation | 403 | ||
Foreign currency translation | ($166) |
Goodwill_and_intangible_assets4
Goodwill and intangible assets (Details) - Schedule of intangible assets (USD $) | Apr. 30, 2015 | Jul. 31, 2014 |
In Thousands, unless otherwise specified | ||
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items] | ||
Finite-lived intangible assets, Gross | $27,909 | $28,478 |
Finite-lived intangible assets, Accumulated Amortization | -21,251 | -20,370 |
Finite-lived intangible assets, Net | 6,658 | 8,108 |
Patents [Member] | ||
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items] | ||
Finite-lived intangible assets, Gross | 11,027 | 11,027 |
Finite-lived intangible assets, Accumulated Amortization | -10,802 | -10,775 |
Finite-lived intangible assets, Net | 225 | 252 |
Customer Relationships [Member] | ||
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items] | ||
Finite-lived intangible assets, Gross | 12,278 | 12,602 |
Finite-lived intangible assets, Accumulated Amortization | -7,162 | -6,565 |
Finite-lived intangible assets, Net | 5,116 | 6,037 |
Website And Acquired Content [Member] | ||
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items] | ||
Finite-lived intangible assets, Gross | 1,023 | 1,037 |
Finite-lived intangible assets, Accumulated Amortization | -1,023 | -1,037 |
Licensed Technology And Other [Member] | ||
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items] | ||
Finite-lived intangible assets, Gross | 515 | 537 |
Finite-lived intangible assets, Accumulated Amortization | -433 | -434 |
Finite-lived intangible assets, Net | 82 | 103 |
Trademarks [Member] | ||
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items] | ||
Finite-lived intangible assets, Gross | 3,066 | 3,275 |
Finite-lived intangible assets, Accumulated Amortization | -1,831 | -1,559 |
Finite-lived intangible assets, Net | $1,235 | $1,716 |
Goodwill_and_intangible_assets5
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions | 9 Months Ended |
Apr. 30, 2015 | |
Minimum [Member] | Customer Relationships [Member] | |
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items] | |
Useful life assigned | 8 years |
Minimum [Member] | Other Intangible Assets [Member] | |
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items] | |
Useful life assigned | 4 years |
Maximum [Member] | Customer Relationships [Member] | |
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items] | |
Useful life assigned | 15 years |
Maximum [Member] | Other Intangible Assets [Member] | |
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items] | |
Useful life assigned | 5 years |
Customer Relationships [Member] | |
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items] | |
Weighted average remaining useful life | 5 years 6 months |
Trademarks [Member] | |
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items] | |
Useful life assigned | 5 years |
Weighted average remaining useful life | 2 years 6 months |
Other Intangible Assets [Member] | |
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items] | |
Weighted average remaining useful life | 6 months |
Loan_Payable_Details
Loan Payable (Details) (USD $) | 9 Months Ended | |
Apr. 30, 2015 | Jul. 31, 2014 | |
Debt Disclosure [Abstract] | ||
Line of Credit Facility Expiration Month and Year | Dec-16 | |
Line of Credit Facility, Maximum Borrowing Capacity | $8,000,000 | |
Line of Credit Facility Additional Borrowings Capacity | 4,000,000 | |
Unamortized Debt Issuance Expense | 281,000 | |
LIBOR Rate Period | 3 months | |
Debt Instrument, Description of Variable Rate Basis | three month LIBOR rate, with a floor of 1.25% plus an applicable margin of 4.0% | |
Debt Instrument, Basis Spread on Variable Rate | 1.25% | |
Debt Instrument Margin on Variable Rate | 4.00% | |
Debt Instrument Increase in Interest Rate on Default | 3.00% | |
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage | 0.50% | |
Line of Credit Facility Minimum Borrowings | 2,000,000 | |
Long-term Line of Credit | 3,013,000 | 3,013,000 |
Line of Credit Facility, Remaining Borrowing Capacity | $2,700,000 |
Accrued_Liabilities_and_Other_2
Accrued Liabilities and Other Current Liabilities (Details) - Accrued liabilities (USD $) | Apr. 30, 2015 | Jul. 31, 2014 |
In Thousands, unless otherwise specified | ||
Accrued liabilities [Abstract] | ||
Legal fee expense | $4,831 | $4,721 |
Payroll, benefits, and commissions | 3,443 | 4,959 |
Professional fees | 654 | 638 |
Research and development | 300 | 400 |
Other | 1,832 | 2,199 |
$11,060 | $12,917 |
Accrued_Liabilities_and_Other_3
Accrued Liabilities and Other Current Liabilities (Details) - Other current liabilities (USD $) | Apr. 30, 2015 | Jul. 31, 2014 |
In Thousands, unless otherwise specified | ||
Accrued Liabilities and Other Current Liabilities (Details) - Other current liabilities [Line Items] | ||
Other Liabilities Current | $851 | $790 |
Accrued Legal Settlement [Member] | ||
Accrued Liabilities and Other Current Liabilities (Details) - Other current liabilities [Line Items] | ||
Other Liabilities Current | 400 | 400 |
Installment Loans [Member] | ||
Accrued Liabilities and Other Current Liabilities (Details) - Other current liabilities [Line Items] | ||
Other Liabilities Current | 302 | 241 |
Capital Lease Obligations [Member] | ||
Accrued Liabilities and Other Current Liabilities (Details) - Other current liabilities [Line Items] | ||
Other Liabilities Current | $149 | $149 |
Other_liabilities_Details
Other liabilities (Details) (USD $) | Apr. 30, 2015 | Jul. 31, 2014 |
Other liabilities (Details) [Line Items] | ||
Other Liabilities, Current | $851,000 | $790,000 |
Accrued Legal Settlement | 1,600,000 | |
Clinical Labs [Member] | Capital Lease Obligation [Member] | ||
Other liabilities (Details) [Line Items] | ||
Capital Leases, Future Minimum Payments, Interest Included in Payments | 37,000 | |
Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments | 516,000 | |
Other Liabilities, Current | 149,000 | |
Clinical Labs [Member] | Installment Loans [Member] | ||
Other liabilities (Details) [Line Items] | ||
Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments | 586,000 | |
Other Liabilities, Current | $302,000 |
Other_liabilities_Details_Sche
Other liabilities (Details) - Schedule of other current liabilities (USD $) | Apr. 30, 2015 | Jul. 31, 2014 |
In Thousands, unless otherwise specified | ||
Other liabilities (Details) - Schedule of other current liabilities [Line Items] | ||
Other liabilities | $1,825 | $2,313 |
Accrued Legal Settlement [Member] | ||
Other liabilities (Details) - Schedule of other current liabilities [Line Items] | ||
Other liabilities | 1,200 | 1,600 |
Capital Lease Obligations [Member] | ||
Other liabilities (Details) - Schedule of other current liabilities [Line Items] | ||
Other liabilities | 249 | 344 |
Installment Loans [Member] | ||
Other liabilities (Details) - Schedule of other current liabilities [Line Items] | ||
Other liabilities | $376 | $369 |
Stockholders_Equity_Details
Stockholders' Equity (Details) (USD $) | 9 Months Ended | |||
Apr. 30, 2015 | Apr. 30, 2014 | Dec. 31, 2014 | Jul. 31, 2014 | |
Stockholders' Equity (Details) [Line Items] | ||||
Common Stock, Par or Stated Value Per Share (in Dollars per share) | $0.01 | $0.01 | ||
Maximum Offering Price Under Sales Agreement | $20,000,000 | $20,000,000 | ||
Percentage of Commission Payable on Equity Offering | 3.00% | |||
Average Sale Price of Stock (in Dollars per share) | $4.34 | $3.23 | ||
Proceeds from Issuance of Common Stock | 6,687,000 | 9,455,000 | ||
Stock Offering and Commissions Expenses | 207,000 | 293,000 | ||
Excess Tax Benefit from Share-based Compensation, Financing Activities | 0 | 0 | ||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options | 600,000 | |||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | 18 months | |||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized | 100,000 | |||
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Outstanding Weighted Average Remaining Contractual Terms | 18 months | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value | 67,000 | 62,000 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares) | 1,297,000 | |||
Stock Issued During Period, Value, Employee Benefit Plan | 663,000 | 636,000 | ||
Common Stock [Member] | ||||
Stockholders' Equity (Details) [Line Items] | ||||
Stock Issued During Period, Shares, New Issues (in Shares) | 1,588,480 | 3,018,112 | ||
Stock Issued During Period, Value, Employee Benefit Plan | $2,000 | |||
Stock Issued During Period, Shares, Employee Benefit Plan (in Shares) | 214,984 | 165,646 |
Stockholders_Equity_Details_Sc
Stockholders' Equity (Details) - Schedule of share-based compensation expense (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, unless otherwise specified | Apr. 30, 2015 | Apr. 30, 2014 | Apr. 30, 2015 | Apr. 30, 2014 |
Stockholders' Equity (Details) - Schedule of share-based compensation expense [Line Items] | ||||
Stock Based Compensation Expense | $113 | $283 | $319 | $497 |
Options [Member] | ||||
Stockholders' Equity (Details) - Schedule of share-based compensation expense [Line Items] | ||||
Stock Based Compensation Expense | 104 | 255 | 283 | 367 |
Restricted Stocks [Member] | ||||
Stockholders' Equity (Details) - Schedule of share-based compensation expense [Line Items] | ||||
Stock Based Compensation Expense | $9 | $28 | $36 | $130 |
Stockholders_Equity_Details_Sc1
Stockholders' Equity (Details) - Schedule of share-based compensation expense by line item (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, unless otherwise specified | Apr. 30, 2015 | Apr. 30, 2014 | Apr. 30, 2015 | Apr. 30, 2014 |
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||||
Share-based Payment Arrangement | $113 | $283 | $319 | $497 |
Cost of Clinical Laboratory Services [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||||
Share-based Payment Arrangement | 3 | 3 | 9 | 7 |
Research and Development Expense [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||||
Share-based Payment Arrangement | 2 | 1 | ||
Selling, General and Administrative Expenses [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||||
Share-based Payment Arrangement | $110 | $280 | $308 | $489 |
Stockholders_Equity_Details_Sc2
Stockholders' Equity (Details) - Schedule of stock option plans (USD $) | 9 Months Ended |
In Thousands, except Share data, unless otherwise specified | Apr. 30, 2015 |
Schedule of stock option plans [Abstract] | |
Outstanding at July 31, 2014 | 1,155,910 |
Outstanding at July 31, 2014 | $5.03 |
Awarded | 383,873 |
Awarded | $3.57 |
Cancelled or expired | -181,900 |
Cancelled or expired | $16.82 |
Outstanding at end of period | 1,357,883 |
Outstanding at end of period | $3.05 |
Outstanding at end of period | 2 years 255 days |
Outstanding at end of period | $39 |
Exercisable at end of period | 782,688 |
Exercisable at end of period | $2.88 |
Exercisable at end of period | 2 years 73 days |
Exercisable at end of period | $20 |
Stockholders_Equity_Details_Sc3
Stockholders' Equity (Details) - Schedule of restricted stock awards (USD $) | 9 Months Ended |
Apr. 30, 2015 | |
Schedule of restricted stock awards [Abstract] | |
Outstanding at July 31, 2014 | 42,502 |
Outstanding at July 31, 2014 | $5.74 |
Awarded | $4.75 |
Awarded | 4,250 |
Vested | -15,419 |
Vested | ($2.41) |
Forfeited | -5,500 |
Forfeited | ($3.32) |
Unvested at end of period | 25,833 |
Unvested at end of period | $8.07 |
Income_taxes_Details
Income taxes (Details) | 3 Months Ended | 9 Months Ended | |
Apr. 30, 2015 | Apr. 30, 2014 | Apr. 30, 2015 | |
Income Tax Disclosure [Abstract] | |||
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | 3.20% | 1.50% | |
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent | 34.00% |
Royalty_and_licensing_income_D
Royalty and licensing income (Details) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Millions, unless otherwise specified | Apr. 30, 2015 | Apr. 30, 2014 | Apr. 30, 2015 | Apr. 30, 2014 |
Royalty and licensing income (Details) [Line Items] | ||||
Patent Expiration Date | 24-Apr-18 | |||
Life Sciences [Member] | ||||
Royalty and licensing income (Details) [Line Items] | ||||
Royalty Revenue | $0.40 | $0.70 | $2.10 | $3.40 |
Segment_reporting_Details
Segment reporting (Details) | 9 Months Ended |
Apr. 30, 2015 | |
Segment Reporting [Abstract] | |
Number of Reportable Segments | 3 |
Segment_reporting_Details_Sche
Segment reporting (Details) - Schedule of segment reporting information, by segment (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, unless otherwise specified | Apr. 30, 2015 | Apr. 30, 2014 | Apr. 30, 2015 | Apr. 30, 2014 |
Revenues: | ||||
Clinical laboratory services | $15,657 | $14,542 | $46,204 | $43,250 |
Product revenues | 7,906 | 8,707 | 23,631 | 24,424 |
Royalty and license fee income | 423 | 729 | 2,067 | 3,366 |
Total revenues | 23,986 | 23,978 | 71,902 | 71,040 |
Operating expenses: | ||||
Cost of clinical laboratory services | 9,724 | 9,784 | 29,100 | 28,785 |
Cost of product revenues | 3,779 | 3,800 | 11,292 | 11,511 |
Research and development | 809 | 849 | 2,434 | 2,498 |
Selling, general and administrative | 10,146 | 10,605 | 30,101 | 31,217 |
Provision for uncollectible accounts receivable | 589 | 684 | 1,731 | 2,468 |
Legal fee expense | 1,955 | 1,911 | 7,225 | 4,788 |
Legal settlements, net | -170 | -3,100 | -170 | -3,100 |
Operating income (loss) | -2,846 | -555 | -9,811 | -7,127 |
Other income (expense) | ||||
Other | 26 | 10 | 28 | 85 |
Foreign exchange gain (loss) | -125 | 144 | -856 | 460 |
Share-based compensation included in above: | ||||
Share-based compensation | 113 | 283 | 319 | 497 |
Clinical Labs [Member] | Cost of Clinical Laboratory Services [Member] | ||||
Share-based compensation included in above: | ||||
Share-based compensation | 3 | 2 | 9 | 6 |
Clinical Labs [Member] | Selling, General and Administrative Expenses [Member] | ||||
Share-based compensation included in above: | ||||
Share-based compensation | 9 | 9 | 30 | 28 |
Clinical Labs [Member] | Total [Member] | ||||
Share-based compensation included in above: | ||||
Share-based compensation | 12 | 11 | 39 | 34 |
Clinical Labs [Member] | ||||
Revenues: | ||||
Clinical laboratory services | 15,657 | 14,542 | 46,204 | 43,250 |
Total revenues | 15,657 | 14,542 | 46,204 | 43,250 |
Operating expenses: | ||||
Cost of clinical laboratory services | 9,724 | 9,784 | 29,100 | 28,785 |
Research and development | 14 | |||
Selling, general and administrative | 4,935 | 5,091 | 15,090 | 15,122 |
Provision for uncollectible accounts receivable | 631 | 684 | 1,820 | 2,448 |
Legal fee expense | 42 | 282 | 174 | 572 |
Legal settlements, net | 2,000 | 2,000 | ||
Total operating expenses | 15,332 | 17,841 | 46,184 | 48,941 |
Operating income (loss) | 325 | -3,299 | 20 | -5,691 |
Other income (expense) | ||||
Interest | -23 | -10 | -63 | -32 |
Other | 11 | 7 | 18 | 34 |
Income (loss) before income taxes | 313 | -3,302 | -25 | -5,689 |
Depreciation and amortization included above | 358 | 351 | 1,072 | 1,061 |
Share-based compensation included in above: | ||||
Capital expenditures | 453 | 90 | 1,042 | 453 |
Life Sciences [Member] | Cost of Clinical Laboratory Services [Member] | ||||
Share-based compensation included in above: | ||||
Share-based compensation | 1 | 1 | ||
Life Sciences [Member] | Research and Development Expense [Member] | ||||
Share-based compensation included in above: | ||||
Share-based compensation | 2 | 1 | ||
Life Sciences [Member] | Selling, General and Administrative Expenses [Member] | ||||
Share-based compensation included in above: | ||||
Share-based compensation | 6 | -4 | 9 | 5 |
Life Sciences [Member] | Total [Member] | ||||
Share-based compensation included in above: | ||||
Share-based compensation | 6 | -3 | 11 | 7 |
Life Sciences [Member] | ||||
Revenues: | ||||
Product revenues | 7,906 | 8,707 | 23,631 | 24,424 |
Royalty and license fee income | 423 | 729 | 2,067 | 3,366 |
Total revenues | 8,329 | 9,436 | 25,698 | 27,790 |
Operating expenses: | ||||
Cost of product revenues | 3,779 | 3,800 | 11,292 | 11,511 |
Research and development | 704 | 599 | 1,887 | 1,668 |
Selling, general and administrative | 3,031 | 3,278 | 8,886 | 10,098 |
Provision for uncollectible accounts receivable | -42 | -89 | 20 | |
Legal fee expense | -22 | 766 | -74 | 803 |
Legal settlements, net | -170 | -5,100 | -170 | -5,100 |
Total operating expenses | 7,280 | 3,343 | 21,732 | 19,000 |
Operating income (loss) | 1,049 | 6,093 | 3,966 | 8,790 |
Other income (expense) | ||||
Interest | 6 | 4 | 13 | 13 |
Other | 2 | -2 | -34 | 18 |
Foreign exchange gain (loss) | -125 | 144 | -856 | 460 |
Income (loss) before income taxes | 932 | 6,239 | 3,089 | 9,281 |
Depreciation and amortization included above | 543 | 614 | 1,656 | 1,876 |
Share-based compensation included in above: | ||||
Capital expenditures | 58 | 36 | 122 | 117 |
Therapeutics [Member] | ||||
Operating expenses: | ||||
Research and development | 105 | 250 | 547 | 816 |
Total operating expenses | 105 | 250 | 547 | 816 |
Operating income (loss) | -105 | -250 | -547 | -816 |
Other income (expense) | ||||
Income (loss) before income taxes | -105 | -250 | -547 | -816 |
Depreciation and amortization included above | 2 | 6 | ||
Other Segments [Member] | Selling, General and Administrative Expenses [Member] | ||||
Share-based compensation included in above: | ||||
Share-based compensation | 95 | 275 | 269 | 456 |
Other Segments [Member] | Total [Member] | ||||
Share-based compensation included in above: | ||||
Share-based compensation | 95 | 275 | 269 | 456 |
Other Segments [Member] | ||||
Operating expenses: | ||||
Selling, general and administrative | 2,180 | 2,236 | 6,125 | 5,997 |
Legal fee expense | 1,935 | 836 | 7,125 | 3,413 |
Total operating expenses | 4,115 | 3,099 | 13,250 | 9,410 |
Operating income (loss) | -4,115 | -3,099 | -13,250 | -9,410 |
Other income (expense) | ||||
Interest | -41 | -41 | -126 | -142 |
Other | 13 | 5 | 44 | 33 |
Income (loss) before income taxes | -4,143 | -3,135 | -13,332 | -9,519 |
Depreciation and amortization included above | 22 | 23 | 67 | 72 |
Share-based compensation included in above: | ||||
Capital expenditures | 4 | 4 | ||
Consolidated [Member] | Cost of Clinical Laboratory Services [Member] | ||||
Share-based compensation included in above: | ||||
Share-based compensation | 3 | 3 | 9 | 7 |
Consolidated [Member] | Research and Development Expense [Member] | ||||
Share-based compensation included in above: | ||||
Share-based compensation | 2 | 1 | ||
Consolidated [Member] | Selling, General and Administrative Expenses [Member] | ||||
Share-based compensation included in above: | ||||
Share-based compensation | 110 | 280 | 308 | 489 |
Consolidated [Member] | Total [Member] | ||||
Share-based compensation included in above: | ||||
Share-based compensation | 113 | 283 | 319 | 497 |
Consolidated [Member] | ||||
Revenues: | ||||
Clinical laboratory services | 15,657 | 14,542 | 46,204 | 43,250 |
Product revenues | 7,906 | 8,707 | 23,631 | 24,424 |
Royalty and license fee income | 423 | 729 | 2,067 | 3,366 |
Total revenues | 23,986 | 23,978 | 71,902 | 71,040 |
Operating expenses: | ||||
Cost of clinical laboratory services | 9,724 | 9,784 | 29,100 | 28,785 |
Cost of product revenues | 3,779 | 3,800 | 11,292 | 11,511 |
Research and development | 809 | 849 | 2,434 | 2,498 |
Selling, general and administrative | 10,146 | 10,605 | 30,101 | 31,217 |
Provision for uncollectible accounts receivable | 589 | 684 | 1,731 | 2,468 |
Legal fee expense | 1,955 | 1,911 | 7,225 | 4,788 |
Legal settlements, net | -170 | -3,100 | -170 | -3,100 |
Total operating expenses | 26,832 | 24,533 | 81,713 | 78,167 |
Operating income (loss) | -2,846 | -555 | -9,811 | -7,127 |
Other income (expense) | ||||
Interest | -58 | -47 | -176 | -161 |
Other | 26 | 10 | 28 | 85 |
Foreign exchange gain (loss) | -125 | 144 | -856 | 460 |
Income (loss) before income taxes | -3,003 | -448 | -10,815 | -6,743 |
Depreciation and amortization included above | 923 | 988 | 2,797 | 3,015 |
Share-based compensation included in above: | ||||
Capital expenditures | 515 | 126 | 1,168 | 570 |
Cost of Clinical Laboratory Services [Member] | ||||
Share-based compensation included in above: | ||||
Share-based compensation | 3 | 3 | 9 | 7 |
Research and Development Expense [Member] | ||||
Share-based compensation included in above: | ||||
Share-based compensation | 2 | 1 | ||
Selling, General and Administrative Expenses [Member] | ||||
Share-based compensation included in above: | ||||
Share-based compensation | $110 | $280 | $308 | $489 |
Contingencies_Details
Contingencies (Details) (USD $) | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||
Nov. 30, 2012 | Jun. 30, 2004 | Apr. 30, 2015 | Apr. 30, 2014 | Apr. 30, 2015 | Apr. 30, 2014 | Jul. 31, 2014 | Jun. 20, 2014 | |
Contingencies (Details) [Line Items] | ||||||||
Gain Contingency, Patents Allegedly Infringed upon, Number | 6 | |||||||
Number of Licensee Patents | 4 | 4 | ||||||
Gain Contingency, Patents Found Not Infringed upon, Number | 1 | |||||||
Gain Contingencies Prejudgement Interest | $12,500,000 | |||||||
Gain (Loss) Related to Litigation Settlement | 170,000 | 3,100,000 | 170,000 | 3,100,000 | ||||
Indemnification Agreement [Member] | ||||||||
Contingencies (Details) [Line Items] | ||||||||
Gain Contingency, Unrecorded Amount | 48,500,000 | 48,500,000 | ||||||
Minimum [Member] | Subpoena [Member] | ||||||||
Contingencies (Details) [Line Items] | ||||||||
Litigation Settlement Period | 2004 | |||||||
Amount of Additional Capital Receipt Condition for Litigation Settlement | 10,000,000 | |||||||
Maximum [Member] | Subpoena [Member] | ||||||||
Contingencies (Details) [Line Items] | ||||||||
Litigation Settlement Period | 2014 | |||||||
Subpoena [Member] | ||||||||
Contingencies (Details) [Line Items] | ||||||||
Investigation Period | The time period initially covered by the investigation was from 2004 through 2011 | |||||||
Estimated Litigation Settlement Amount | 2,000,000 | |||||||
Period Over Which Settlement Amount Has to Be Paid | 5 years | |||||||
Estimated Litigation Liability, Current | 400,000 | 400,000 | ||||||
Estimated Litigation Liability, Noncurrent | 1,200,000 | 1,200,000 | ||||||
Additional Payment of Litigation Settlement Amount | 1,500,000 | |||||||
Percentage of Additional Payment of Litigation Settlement Amount over Additional Capital Receipt | 20.00% | |||||||
Perkin Elmer [Member] | ||||||||
Contingencies (Details) [Line Items] | ||||||||
Escrow Deposit | $7,000,000 |